|
C11ORF57 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.99970000137296E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.4565999999494E-06 |
| Normal-vs-Stage2 |
4.190500E-04 |
| Normal-vs-Stage3 |
5.81950043709867E-11 |
| Normal-vs-Stage4 |
3.36659999877753E-09 |
| Stage1-vs-Stage2 |
5.598000E-01 |
| Stage1-vs-Stage3 |
2.741400E-03 |
| Stage1-vs-Stage4 |
8.639200E-03 |
| Stage2-vs-Stage3 |
1.262020E-02 |
| Stage2-vs-Stage4 |
1.012070E-02 |
| Stage3-vs-Stage4 |
7.834200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.15039999643218E-08 |
| Normal-vs-AfricanAmerican |
1.260500E-03 |
| Normal-vs-Asian |
9.54770000000105E-05 |
| Caucasian-vs-AfricanAmerican |
6.244000E-01 |
| Caucasian-vs-Asian |
5.941500E-02 |
| AfricanAmerican-vs-Asian |
5.809400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.41889999749623E-09 |
| Normal-vs-Female |
2.28410000024937E-07 |
| Male-vs-Female |
2.768600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.56190000000223E-06 |
| Normal-vs-Age(41-60Yrs) |
4.96569996233376E-09 |
| Normal-vs-Age(61-80Yrs) |
1.48590000303983E-08 |
| Normal-vs-Age(81-100Yrs) |
1.183200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.970400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.163600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.002200E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.303010E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.401700E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.070430E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.024010E-02 |
| Classical-VS-Follicular |
2.393200E-01 |
| Classical-VS-Other |
9.684200E-01 |
| Classical-VS-Normal |
8.63210000034975E-07 |
| Tall-VS-Follicular |
1.662030E-03 |
| Tall-VS-Other |
3.497200E-01 |
| Tall-VS-Normal |
5.38769995284127E-09 |
| Follicular-VS-Other |
7.615200E-01 |
| Follicular-VS-Normal |
7.93199999999938E-05 |
| Other-VS-Normal |
5.412300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.2523000010064E-08 |
| Normal-vs-N1 |
5.57529999944961E-09 |
| N0-vs-N1 |
2.435900E-02 |
|
|
